Compare ASTRAZENECA PHARMA with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs STERLING BIOTECH - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA STERLING BIOTECH ASTRAZENECA PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 73.6 -0.4 - View Chart
P/BV x 20.7 0.0 145,569.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
STERLING BIOTECH
Dec-13
ASTRAZENECA PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,27811 12,171.4%   
Low Rs8833 25,958.8%   
Sales per share (Unadj.) Rs228.426.8 852.0%  
Earnings per share (Unadj.) Rs10.4-15.0 -69.3%  
Cash flow per share (Unadj.) Rs16.3-5.5 -297.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.854.9 180.0%  
Shares outstanding (eoy) m25.00267.87 9.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.70.3 1,824.3%   
Avg P/E ratio x104.2-0.5 -22,432.3%  
P/CF ratio (eoy) x66.4-1.3 -5,222.1%  
Price / Book Value ratio x10.90.1 8,636.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0081,862 1,450.7%   
No. of employees `0001.41.4 100.1%   
Total wages/salary Rs m1,535547 280.8%   
Avg. sales/employee Rs Th4,210.95,303.3 79.4%   
Avg. wages/employee Rs Th1,132.2403.8 280.4%   
Avg. net profit/employee Rs Th191.1-2,959.0 -6.5%   
INCOME DATA
Net Sales Rs m5,7107,181 79.5%  
Other income Rs m12343 287.6%   
Total revenues Rs m5,8337,223 80.7%   
Gross profit Rs m463947 48.9%  
Depreciation Rs m1472,543 5.8%   
Interest Rs m04,377 0.0%   
Profit before tax Rs m438-5,931 -7.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179-1,924 -9.3%   
Profit after tax Rs m259-4,007 -6.5%  
Gross profit margin %8.113.2 61.5%  
Effective tax rate %40.832.4 125.9%   
Net profit margin %4.5-55.8 -8.1%  
BALANCE SHEET DATA
Current assets Rs m3,20914,335 22.4%   
Current liabilities Rs m2,07049,809 4.2%   
Net working cap to sales %20.0-494.0 -4.0%  
Current ratio x1.60.3 538.8%  
Inventory Days Days72403 17.9%  
Debtors Days Days35171 20.5%  
Net fixed assets Rs m79055,432 1.4%   
Share capital Rs m50268 18.7%   
"Free" reserves Rs m2,41913,935 17.4%   
Net worth Rs m2,46914,701 16.8%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m4,60573,988 6.2%  
Interest coverage xNM-0.4-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.1 1,277.5%   
Return on assets %5.60.5 1,123.2%  
Return on equity %10.5-27.3 -38.5%  
Return on capital %17.7-6.4 -276.0%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m3001,860 16.1%   
Fx outflow Rs m2,01525 8,095.3%   
Net fx Rs m-1,7151,835 -93.5%   
CASH FLOW
From Operations Rs m881,719 5.1%  
From Investments Rs m-94-3,148 3.0%  
From Financial Activity Rs mNA1,426 0.0%  
Net Cashflow Rs m-6-3 167.6%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 15.7 9.9 158.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 9.1 39.3 23.2%  
Shareholders   12,856 21,482 59.8%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  NOVARTIS  PANACEA BIOTECH  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS